

Endovia Health Sciences, Inc. (EDVA)

NYSE; consumer nondurables; SIC 2080, Beverages; CIK 0001553788

Endovia Health Sciences, Inc. EDVA; consumer nondurables			
Grade	E A B C D E weakest fifth of 124 graded peers percentile 98.4; sampling error 3.8 points; lower is stronger	 E, the bear weakest fifth of its sector; letters are fifths of the 124 graded peers	
Rank	122 of 124		
Profitability	C percentile 46.9		
Solvency	E percentile 93.2		
Growth and financing	E percentile 99.6		
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025		
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025		
Size band	under \$12.5M assets total assets \$965,694		
Standard universe	outside revenue above \$1M and assets above \$10M		
Warnings	short runway, late filer, degenerate inputs; fortress balance sheet not computable: dilution, distress		
Inputs computable	7 of 14		
Graded from	filings received through Apr 30, 2026 162 days before the rescen; latest periodic filing 10-Q received Aug 19, 2026		
Last close	\$0.15 2026-10-08; market equity \$983,681		
Price used in grade	None		
		Share price, twelve months to the rescen split-adjusted close; the letter is fixed at the rescen that set it 	
		Rescens on file: B from Mar 21, 2025, B/C from May 21, 2025, B from Jun 21, 2025	

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Apr 15, 2026

The disclosure set forth in "Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - Warrants" is incorporated During the three-month period ended December 31, 2025, no officer or director has adopted any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement within the meaning of Item 408 of Regulation S-K promulgated under the Securities Act of 1933. ITEM 9C. DISCLOSURE REGARDING FOREIGN

JURISDICTIONS THAT PREVENT INSPECTIONS.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 46.9						
Gross profitability		1.7%	29.8%	93.8	146	2025-12-31
Return on invested capital		not computable	5.6%			one or more required annual facts are missing
Accruals ratio		(1,096.1%)	(5.0%)	0.0	153	2025-12-31
Gross margin stability, five years		not computable	1.9 pts			annual revenue must exceed \$100,000
Solvency, sleeve percentile 93.2						
Twelve-month failure probability		not computable	0.03%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(819.93)	3.11	100.0	122	2025-12-31
Net debt to EBITDA		not computable	2.54x			EBITDA must exceed \$100,000
Interest coverage		(5.62x)	2.51x	81.0	43	2025-12-31
Current ratio		0.04x	1.81x	98.7	157	2025-12-31
Growth and financing, sleeve percentile 99.6						
Revenue growth, three-year compound		(84.1%)	0.2%	100.0	133	2025-12-31
Free cash flow growth, three-year compound		not computable	14.9%			four consecutive annual FCF observations are required; found 9
Reinvestment rate		not computable	10.7%			one or more required annual facts are missing
Asset growth, three years		(61.8%)	0.5%	99.2	134	2025-12-31
Net share issuance, one year		not computable	0.05%			prior share count is 8 days earlier


Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 0.5 months
Late filer	found 7 NT 10-K/Q filings in the last eight quarters
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor
Fortress balance sheet	cash minus debt is 278,017 USD; Altman Z is not used

Among 124 peers

consumer nondurables; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
117	Culp Inc. (CULP)	94.3	E	fortress balance sheet
118	Mondelez International, Inc. (MDLZ)	95.1	E	
119	Hain Celestial Group Inc. (HAIN)	95.9	E	fortress balance sheet
120	Limoneira Co. (LMNR)	96.7	E	
121	Reed'S, Inc. (REED)	97.6	E	
122	Endovia Health Sciences, Inc. (EDVA) <	98.4	E	short runway, late filer, degenerate inputs, fortress balance sheet
123	22nd Century Group, Inc. (XXII)	99.2	E	dilution, fortress balance sheet
124	Planet Green Holdings Corp. (PLAG)	100.0	E	dilution, late filer, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(96.8%)	(0.2%)	2
Distance from 52-week high	(98.4%)	(24.8%)	2
EBIT to enterprise value	(1,810.6%)	4.1%	0
Free cash flow yield	(712.6%)	4.8%	1
Book value to price	(15.36)	0.57	0
Sales to price	0.07	1.20	0
Composite equity issuance, five years	not computable	(16.3%)	
Relative strength against the sector, log excess return	(3.54)	(0.10)	2

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$242,702
Operating cash flow, four quarters	-\$5.5M
Months of runway	0.5
Days since last periodic filing	51 (10-Q received Aug 19, 2026)
Median daily dollar volume, 63 sessions	\$151,454

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$16,898	2025-12-31	2026-04-15	10-K	0001731122-26-000577
2	assets	us-gaap:Assets	\$965,694	2025-12-31	2026-04-15	10-K	0001731122-26-000577
3	net income	us-gaap:NetIncomeLoss	-\$25.2M	2025-12-31	2026-04-15	10-K	0001731122-26-000577
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$4.8M	2025-12-31	2026-04-15	10-K	0001731122-26-000577
5	assets	us-gaap:Assets	\$2.8M	2024-12-31	2026-04-15	10-K	0001731122-26-000577
6	revenue	us-gaap:Revenues	\$73,066	2025-12-31	2026-04-15	10-K	0001731122-26-000577
7	current assets	us-gaap:AssetsCurrent	\$631,993	2025-12-31	2026-04-15	10-K	0001731122-26-000577
8	current liabilities	us-gaap:LiabilitiesCurrent	\$16.3M	2025-12-31	2026-04-15	10-K	0001731122-26-000577
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$181.9M	2025-12-31	2026-04-15	10-K	0001731122-26-000577
10	operating income	us-gaap:OperatingIncomeLoss	-\$14.2M	2025-12-31	2026-04-15	10-K	0001731122-26-000577
11	book equity	us-gaap:StockholdersEquity	-\$15.3M	2025-12-31	2026-04-15	10-K	0001731122-26-000577
12	liabilities	us-gaap:Liabilities	\$16.3M	2025-12-31	2026-04-15	10-K	0001731122-26-000577
13	total debt	us-gaap:LongTermDebt	\$3,418	2025-12-31	2026-04-15	10-K	0001731122-26-000577
14	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$281,435	2025-12-31	2026-04-15	10-K	0001731122-26-000577
15	depreciation amortization	us-gaap:Depreciation	\$148,070	2025-12-31	2026-04-15	10-K	0001731122-26-000577
16	interest expense	us-gaap:InterestExpense	\$2.5M	2025-12-31	2026-04-15	10-K	0001731122-26-000577
17	revenue	us-gaap:Revenues	\$801,273	2024-12-31	2026-04-15	10-K	0001731122-26-000577
18	revenue	us-gaap:Revenues	\$18.9M	2023-12-31	2025-07-11	10-K	0001731122-25-000964
19	revenue	us-gaap:Revenues	\$18.1M	2022-12-31	2024-03-29	10-K	0001731122-24-000539
20	assets	us-gaap:Assets	\$9.9M	2023-12-31	2025-07-11	10-K	0001731122-25-000964
21	assets	us-gaap:Assets	\$17.3M	2022-12-31	2024-03-29	10-K	0001731122-24-000539
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,858,508	2026-04-22	2026-04-30	10-K/A	0001731122-26-000640
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,953,538	2026-04-14	2026-04-15	10-K	0001731122-26-000577